J.D. Power study: Pharmacist, patient interaction increasingly important in pharmacy customer satisfaction
The importance of customers interacting with a pharmacist increased across the four pharmacy segments in 2014, the study showed. Satisfaction improves notably when pharmacists explain the potential side effects of medication to customers as well as costs they may incur. In brick and mortar stores, speaking with a pharmacist increases store spending.
Having an in-store clinic or wellness center increases satisfaction with brick and mortar pharmacies by 42 points; increases the likelihood that customers will say they “strongly agree” that they feel loyal to their pharmacy by 6 percentage points; and leads to a larger basket of goods purchased in the store by 8 percentage points;
Pharmacist satisfaction is highest in the chain drug store segment (883), followed by the supermarket (877) and mass merchandiser (864) segments. Non-pharmacist staff satisfaction is highest among supermarket pharmacies (847), followed by chain drug store (841) and mass merchandiser (820) pharmacies;
Satisfaction is higher when a pharmacy and customer collaborate on a plan to help ensure that the customer does not miss a dose of their medication, particularly those with a 30-day supply. Across pharmacy segments, the percentage of customers who report running out of medication before they can refill it is 13% for chain drug stores; 14% for supermarket pharmacies; 15% for mass merchandisers; and 10% for mail order pharmacies;
Providing a thorough explanation of risks and side effects of medication across multiple communication channels, both in writing and verbally, reinforces the pharmacy-customer relationship in quality care and wellness. Brick and mortar stores meet this Key Performance Indicator 33% of the time; and
- Customer interaction with a pharmacist impacts additional store purchases. Among customers who speak directly with a pharmacist in a chain drug store, 29% purchase an OTC medication and 59% purchase an additional non-pharmaceutical product to go with their prescription. More than one-fifth (21%) of customers indicate the pharmacist answered a cost related question.
NACDS reflects, looks ahead on 30th anniversary of ‘Hatch-Waxman’ Act
ARLINGTON, Va. — In celebration of the 30th anniversary of the enactment of the Drug Price Competition and Patent Term Restoration Act, also known as the “Hatch-Waxman” Act, the National Association of Chain Drug Stores issued a statement to reflect on the evolution of providing patient access to generic medications and noted that it is looking forward to further progress in the years ahead.
“We laud the efforts of lawmakers such as Senator Orrin Hatch, R-Utah, and Rep. Henry Waxman, D-Calif., for their forward-thinking leadership in opening the door to make generic drugs more affordable and accessible for patients,” stated NACDS president and CEO Steve Anderson. “As the landscape of the healthcare system has transformed in the last 30 years, generic drugs have long-surpassed the expected impact of how they would be utilized by patients.”
When enacted in 1984, it was projected that the legislation could save Americans $1 billion. Fast-forward to 2013, the Generic Drug Savings in the U.S. report, compiled by IMS Institute for Healthcare Informatics, showed that generics saved $239 billion.
“Chain pharmacy is committed to helping patients obtain cost-effective healthcare. Looking ahead to the next 30 years, we need to continue to find ways to make prescription drugs more affordable for patients,” Anderson stated.
NACDS has long-promoted policies that facilitate patient access to cost effective medications, and continues to do so in the growing area of biologic drugs: 1) patients need greater access to the generic versions of costly biologic drugs, and 2) pharmacists in all states should have the ability to substitute approved interchangeable biosimilar medications.
NACDS noted that biologic drugs, which can drastically improve patient health, are highly expensive medications. Under legislation enacted in 2010, a drug approval process was created so the Food and Drug Administration can approve generic versions of biologic drugs — known as biosimilars — with the intent of providing patients with more affordable options for these types of products. NACDS stated that it continues to work with the FDA to urge the agency to adopt policies that will facilitate greater access to biosimilar medications.
In addition, state generic substitution laws were enacted decades ago, well before the approval pathway for biosimilars was conceived. As such, the language in these state laws does not recognize or accommodate the substitution of interchangeable biosimilar drugs. According to NACDS, this must be remedied so that pharmacists can substitute interchangeable biosimilar drugs consistent with existing substitution practices for other generic drugs, and continue to help patients and payors by controlling prescription drug costs and saving overall healthcare dollars.
“We look forward to working with our industry partners like the Generic Pharmaceutical Association and others, as well as the lawmakers and policy makers to continue building on the success of the ‘Hatch-Waxman’ Act in providing affordable access to generic medications for patients,” Anderson stated.
In commenting on the anniversary of the “Hatch-Waxman” Act, GPhA president and CEO, Ralph G. Neas, stated, “Today, the generic industry’s future could not be brighter. The Hatch-Waxman law created a strong foundation for a dynamic and evolving generic drug industry, and with emerging opportunities from a global marketplace, expanded health coverage access, and the needs of an aging population, the industry has never been stronger. As we look forward to the next frontier of affordable medicines, biosimilars, a recent study by Express Scripts estimates that hundreds of billions of dollars in savings are at stake. Over 10 years, the report showed, the United States would save $250 billion if just the 11 likeliest biosimilars would enter the market.”
Neas added, “We must embrace the spirit of the Hatch-Waxman law and build on its remarkable achievements. It is essential to recognize that balancing competition with access to affordable medicines can revolutionize the market, offer consumers quality and safe choices, and inspire innovation. ”
Revlon CFO Lawrence Alletto steps down
NEW YORK — Revlon revealed in a filing with the Securities and Exchange Commission that, effective Sept. 30, Lawrence Alletto, its EVP, CFO and chief administrative officer, is leaving the company after about a year on the job to pursue other opportunities.
In the SEC filing, Revlon stated that, “Alletto’s departure from the company is not the result of any issue or concern with the company’s accounting, financial reporting or internal control over financial reporting.”
Succeeding Alletto is Roberto Simon, who will assume the role of EVP and CFO, effective Sept. 30.
Previously, Simon served as the company’s SVP, global finance since joining the company in October 2013 as part of its acquisition of The Colomer Group. Prior to joining the company and since 2002, Simon served in various senior finance positions of increasing responsibility at The Colomer Group, including most recently serving as The Colomer Group’s CFO since October 2011.
Alletto has worked together with Simon to ensure a smooth transition of the company's financial functions.